Life is a health journey for people affected by multiple sclerosis. Approximately 2.5 million people worldwide are affected by this disorder which attacks the central nervous system, damaging the myelin sheath – the protective layer covering the nerves that carry signals between the brain and spinal cord and the rest of the body. Multiple sclerosis affects each person differently with symptoms ranging from numbness in the limbs or forgetfulness to paralysis or loss of vision.
Going beyond the treatment of disease
As a health journey partner, Sanofi Genzyme our global specialty care business unit have been working for over a decade on the development of treatments for multiple sclerosis and we are committed to provide patients, including those in emerging markets (1), with healthcare solutions. Building on our experience working with small patient populations in rare diseases, we strive to develop relationships with patients and caregivers, healthcare providers and advocacy organizations to better understand the challenges faced by people living with multiple sclerosis.
Future advancements
Sanofi currently has two treatment options available to patients. However, we recognize there remain unmet needs for some MS patients. We continue to focus our Research & Development efforts in areas where we believe we have the potential to help the MS community. These include early-stage research programs that focus on preventing and repairing the damage to the nervous system caused by MS.
For more information about our work in multiple sclerosis, please consult the Sanofi Genzyme website.
(1) Emerging markets: world excluding U.S., Canada, Western Europe (France, Germany, UK, Italy, Spain, Greece, Cyprus, Malta, Belgium, Luxembourg, Portugal, the Netherlands, Austria, Switzerland, Sweden, Ireland, Finland, Norway, Iceland, Denmark), Japan, South Korea, Australia and New Zealand
